

Andre Goy, MD

John Theurer Cancer Center at HUMC , NJ

Dr. Goy is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma and HIV-associated lymphoma. As chief of John Theurer Cancer Center's Division of Lymphoma, he leads New Jersey's largest program for research, treatment and management of lymphoma. Dr. Goy has trained and worked at some of the world's leading medical institutions, including Memorial Sloan-Kettering Cancer Center; The University of Texas M.D. Anderson Cancer Center; University Hospitals Group of l' Assistance Publique in Paris, France; and Pasteur Institute in Paris.



- Dr. Goy is widely-known for his clinical research in NHL especially mantle cell lymphoma and he is a member of LRF's Mantle Cell Lymphoma Consortium. Dr Goy first showed evidence of activity of bortezomib in mantle cell lymphoma and was co-PI on the pivotal trial, which led to FDA approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma in 2006. He is currently the global PI on the pivotal trial of lenalidomide in MCL and participates in many additional trials in MCL and other lymphomas.
- Dr. Goy was instrumental in developing the John Theurer Cancer Center's Tissue Bank, and developing an outcome database for patients in the tissue repository.
- Dr. Goy's research centers on developing novel targeted therapies for lymphoma and the development of biomarkers for lymphoma.
- He has been invited to speak and teach around the world, and his research has been published extensively with more than 60 articles, multiple book chapters and more than 200 abstracts presented at national and international conferences.
- He is the reviewer of several journals including Journal of Clinical Oncology, Blood, Cancer, American Journal of Hematology, Cancer Research, Clinical Cancer research, Leukemia and Lymphoma, Clinical Lymphoma, Clinical Breast, Hematologica and Lancet Oncology.
- Dr Goy was named Chairman of Oncology and Director of the John Theurer Cancer Center in 2011, a center which performed last year more than 350 stem cell transplants (1/2 allogenic) and which by volume of cancer care is among the top 10 cancer programs in the nation.